Castello et al. [27] reported PSA flare in 9.5–35.7% of prostate cancer patients treated with Ra-223, while better OS was noted in mCRPC patients experiencing PSA flare during Ra-233 therapy as compared to those with a progressive PSA increase. The gene discussed is KLK3; the disease is prostate carcinoma.